311 related articles for article (PubMed ID: 26130651)
1. RAS/MAPK Activation Drives Resistance to Smo Inhibition, Metastasis, and Tumor Evolution in Shh Pathway-Dependent Tumors.
Zhao X; Ponomaryov T; Ornell KJ; Zhou P; Dabral SK; Pak E; Li W; Atwood SX; Whitson RJ; Chang AL; Li J; Oro AE; Chan JA; Kelleher JF; Segal RA
Cancer Res; 2015 Sep; 75(17):3623-35. PubMed ID: 26130651
[TBL] [Abstract][Full Text] [Related]
2. Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition.
Kool M; Jones DT; Jäger N; Northcott PA; Pugh TJ; Hovestadt V; Piro RM; Esparza LA; Markant SL; Remke M; Milde T; Bourdeaut F; Ryzhova M; Sturm D; Pfaff E; Stark S; Hutter S; Seker-Cin H; Johann P; Bender S; Schmidt C; Rausch T; Shih D; Reimand J; Sieber L; Wittmann A; Linke L; Witt H; Weber UD; Zapatka M; König R; Beroukhim R; Bergthold G; van Sluis P; Volckmann R; Koster J; Versteeg R; Schmidt S; Wolf S; Lawerenz C; Bartholomae CC; von Kalle C; Unterberg A; Herold-Mende C; Hofer S; Kulozik AE; von Deimling A; Scheurlen W; Felsberg J; Reifenberger G; Hasselblatt M; Crawford JR; Grant GA; Jabado N; Perry A; Cowdrey C; Croul S; Zadeh G; Korbel JO; Doz F; Delattre O; Bader GD; McCabe MG; Collins VP; Kieran MW; Cho YJ; Pomeroy SL; Witt O; Brors B; Taylor MD; Schüller U; Korshunov A; Eils R; Wechsler-Reya RJ; Lichter P; Pfister SM;
Cancer Cell; 2014 Mar; 25(3):393-405. PubMed ID: 24651015
[TBL] [Abstract][Full Text] [Related]
3. A large-scale drug screen identifies selective inhibitors of class I HDACs as a potential therapeutic option for SHH medulloblastoma.
Pak E; MacKenzie EL; Zhao X; Pazyra-Murphy MF; Park PMC; Wu L; Shaw DL; Addleson EC; Cayer SS; Lopez BG; Agar NYR; Rubin LL; Qi J; Merk DJ; Segal RA
Neuro Oncol; 2019 Sep; 21(9):1150-1163. PubMed ID: 31111916
[TBL] [Abstract][Full Text] [Related]
4. Loss of Primary Cilia Drives Switching from Hedgehog to Ras/MAPK Pathway in Resistant Basal Cell Carcinoma.
Kuonen F; Huskey NE; Shankar G; Jaju P; Whitson RJ; Rieger KE; Atwood SX; Sarin KY; Oro AE
J Invest Dermatol; 2019 Jul; 139(7):1439-1448. PubMed ID: 30707899
[TBL] [Abstract][Full Text] [Related]
5. A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors.
Rodon J; Tawbi HA; Thomas AL; Stoller RG; Turtschi CP; Baselga J; Sarantopoulos J; Mahalingam D; Shou Y; Moles MA; Yang L; Granvil C; Hurh E; Rose KL; Amakye DD; Dummer R; Mita AC
Clin Cancer Res; 2014 Apr; 20(7):1900-9. PubMed ID: 24523439
[TBL] [Abstract][Full Text] [Related]
6. Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists.
Kim J; Aftab BT; Tang JY; Kim D; Lee AH; Rezaee M; Kim J; Chen B; King EM; Borodovsky A; Riggins GJ; Epstein EH; Beachy PA; Rudin CM
Cancer Cell; 2013 Jan; 23(1):23-34. PubMed ID: 23291299
[TBL] [Abstract][Full Text] [Related]
7. A computational study of hedgehog signalling involved in basal cell carcinoma reveals the potential and limitation of combination therapy.
Buetti-Dinh A; Jensen R; Friedman R
BMC Cancer; 2018 May; 18(1):569. PubMed ID: 29776351
[TBL] [Abstract][Full Text] [Related]
8. Protein kinase A activation inhibits oncogenic Sonic hedgehog signalling and suppresses basal cell carcinoma of the skin.
Makinodan E; Marneros AG
Exp Dermatol; 2012 Nov; 21(11):847-52. PubMed ID: 23163650
[TBL] [Abstract][Full Text] [Related]
9. Hedgehog fights back: mechanisms of acquired resistance against Smoothened antagonists.
Metcalfe C; de Sauvage FJ
Cancer Res; 2011 Aug; 71(15):5057-61. PubMed ID: 21771911
[TBL] [Abstract][Full Text] [Related]
10. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma.
Yauch RL; Dijkgraaf GJ; Alicke B; Januario T; Ahn CP; Holcomb T; Pujara K; Stinson J; Callahan CA; Tang T; Bazan JF; Kan Z; Seshagiri S; Hann CL; Gould SE; Low JA; Rudin CM; de Sauvage FJ
Science; 2009 Oct; 326(5952):572-4. PubMed ID: 19726788
[TBL] [Abstract][Full Text] [Related]
11. scRNA-seq in medulloblastoma shows cellular heterogeneity and lineage expansion support resistance to SHH inhibitor therapy.
Ocasio JK; Babcock B; Malawsky D; Weir SJ; Loo L; Simon JM; Zylka MJ; Hwang D; Dismuke T; Sokolsky M; Rosen EP; Vibhakar R; Zhang J; Saulnier O; Vladoiu M; El-Hamamy I; Stein LD; Taylor MD; Smith KS; Northcott PA; Colaneri A; Wilhelmsen K; Gershon TR
Nat Commun; 2019 Dec; 10(1):5829. PubMed ID: 31863004
[TBL] [Abstract][Full Text] [Related]
12. Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma.
Buonamici S; Williams J; Morrissey M; Wang A; Guo R; Vattay A; Hsiao K; Yuan J; Green J; Ospina B; Yu Q; Ostrom L; Fordjour P; Anderson DL; Monahan JE; Kelleher JF; Peukert S; Pan S; Wu X; Maira SM; García-Echeverría C; Briggs KJ; Watkins DN; Yao YM; Lengauer C; Warmuth M; Sellers WR; Dorsch M
Sci Transl Med; 2010 Sep; 2(51):51ra70. PubMed ID: 20881279
[TBL] [Abstract][Full Text] [Related]
13. SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer.
Della Corte CM; Bellevicine C; Vicidomini G; Vitagliano D; Malapelle U; Accardo M; Fabozzi A; Fiorelli A; Fasano M; Papaccio F; Martinelli E; Troiani T; Troncone G; Santini M; Bianco R; Ciardiello F; Morgillo F
Clin Cancer Res; 2015 Oct; 21(20):4686-97. PubMed ID: 26124204
[TBL] [Abstract][Full Text] [Related]
14. Phosphoproteomics of short-term hedgehog signaling in human medulloblastoma cells.
Scheidt T; Alka O; Gonczarowska-Jorge H; Gruber W; Rathje F; Dell'Aica M; Rurik M; Kohlbacher O; Zahedi RP; Aberger F; Huber CG
Cell Commun Signal; 2020 Jun; 18(1):99. PubMed ID: 32576205
[TBL] [Abstract][Full Text] [Related]
15. Relation between sonic hedgehog pathway gene polymorphisms and basal cell carcinoma development in the Polish population.
Lesiak A; Sobolewska-Sztychny D; Majak P; Sobjanek M; Wodz K; Sygut KP; Majsterek I; Wozniacka A; Narbutt J
Arch Dermatol Res; 2016 Jan; 308(1):39-47. PubMed ID: 26590974
[TBL] [Abstract][Full Text] [Related]
16. Smoothened variants explain the majority of drug resistance in basal cell carcinoma.
Atwood SX; Sarin KY; Whitson RJ; Li JR; Kim G; Rezaee M; Ally MS; Kim J; Yao C; Chang AL; Oro AE; Tang JY
Cancer Cell; 2015 Mar; 27(3):342-53. PubMed ID: 25759020
[TBL] [Abstract][Full Text] [Related]
17. CD271
Liang L; Coudière-Morrison L; Tatari N; Stromecki M; Fresnoza A; Porter CJ; Del Bigio MR; Hawkins C; Chan JA; Ryken TC; Taylor MD; Ramaswamy V; Werbowetski-Ogilvie TE
Cancer Res; 2018 Aug; 78(16):4745-4759. PubMed ID: 29930101
[TBL] [Abstract][Full Text] [Related]
18. Smoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma.
Pricl S; Cortelazzi B; Dal Col V; Marson D; Laurini E; Fermeglia M; Licitra L; Pilotti S; Bossi P; Perrone F
Mol Oncol; 2015 Feb; 9(2):389-97. PubMed ID: 25306392
[TBL] [Abstract][Full Text] [Related]
19. Small-molecule modulators of the Sonic Hedgehog signaling pathway.
Stanton BZ; Peng LF
Mol Biosyst; 2010 Jan; 6(1):44-54. PubMed ID: 20024066
[TBL] [Abstract][Full Text] [Related]
20. A CK1α Activator Penetrates the Brain and Shows Efficacy Against Drug-resistant Metastatic Medulloblastoma.
Rodriguez-Blanco J; Li B; Long J; Shen C; Yang F; Orton D; Collins S; Kasahara N; Ayad NG; McCrea HJ; Roussel MF; Weiss WA; Capobianco AJ; Robbins DJ
Clin Cancer Res; 2019 Feb; 25(4):1379-1388. PubMed ID: 30487124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
